Insulet Corporation
- Industria
- Medical Devices
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 15 de mayo de 2007
- Empleados
- 5400
- Sitio web
- www.insulet.com
Rango de valoración compuesto · conservador $110–$120 / razonable $120–$160 / optimista $170–$190. A $145.76, Dentro del rango de valor intrínseco razonable.
Al publicar $144.94 (31 de mayo de 2026)
Aún no hay análisis sobre este valor en tu idioma.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Historia
PróximamenteEsta sección se está completando; vuelve pronto.
Posición en el sector
PróximamenteEsta sección se está completando; vuelve pronto.
